U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C4H6N4O3S2
Molecular Weight 222.245
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACETAZOLAMIDE

SMILES

CC(=O)NC1=NN=C(S1)S(N)(=O)=O

InChI

InChIKey=BZKPWHYZMXOIDC-UHFFFAOYSA-N
InChI=1S/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9)

HIDE SMILES / InChI

Molecular Formula C4H6N4O3S2
Molecular Weight 222.245
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Acetazolamide, usually sold under the trade name Diamox in some countries. DIAMOX is used for adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. DIAMOX is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness despite gradual ascent. DIAMOX is an enzyme inhibitor that acts specifically on carbonic anhydrase, the enzyme that catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In the eye, this inhibitory action of acetazolamide decreases the secretion of aqueous humor and results in a drop in intraocular pressure, a reaction considered desirable in cases of glaucoma and even in certain non-glaucomatous conditions. Evidence seems to indicate that DIAMOX has utility as an adjuvant in treatment of certain dysfunctions of the central nervous system (e.g., epilepsy). The diuretic effect of DIAMOX is due to its action in the kidney on the reversible reaction involving hydration of carbon dioxide and dehydration of carbonic acid. The result is renal loss of HCO3 ion, which carries out sodium, water, and potassium. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
DIAMOX

Approved Use

For adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. DIAMOX is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness despite gradual ascent.

Launch Date

-5.18572802E11
Preventing
DIAMOX

Approved Use

For adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. DIAMOX is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness despite gradual ascent.

Launch Date

-5.18572802E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
776 ng/mL
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ACETAZOLAMIDE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1313 ng/mL
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ACETAZOLAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
52130 ng × h/mL
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ACETAZOLAMIDE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6735 ng × h/mL
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ACETAZOLAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
42.4 h
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ACETAZOLAMIDE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
13.1 h
15 mg 1 times / day multiple, oral
dose: 15 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ACETAZOLAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
unknown, oral
ACETAZOLAMIDE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy, 21–80 years
n = 52
Health Status: unhealthy
Condition: elevated intraocular pressure
Age Group: 21–80 years
Sex: M+F
Population Size: 52
Sources:
Disc. AE: Leukopenia...
AEs leading to
discontinuation/dose reduction:
Leukopenia
Sources:
500 mg 4 times / day multiple, oral
Studied dose
Dose: 500 mg, 4 times / day
Route: oral
Route: multiple
Dose: 500 mg, 4 times / day
Sources:
unhealthy, 70 years
n = 1
Health Status: unhealthy
Condition: Diabetes | Chronic Renal Failure
Age Group: 70 years
Sex: F
Population Size: 1
Sources:
Other AEs: Metabolic acidosis, Coma...
Other AEs:
Metabolic acidosis (grade 3)
Coma
Sources:
AEs

AEs

AESignificanceDosePopulation
Leukopenia Disc. AE
250 mg 4 times / day multiple, oral
Recommended
Dose: 250 mg, 4 times / day
Route: oral
Route: multiple
Dose: 250 mg, 4 times / day
Sources:
unhealthy, 21–80 years
n = 52
Health Status: unhealthy
Condition: elevated intraocular pressure
Age Group: 21–80 years
Sex: M+F
Population Size: 52
Sources:
Coma
500 mg 4 times / day multiple, oral
Studied dose
Dose: 500 mg, 4 times / day
Route: oral
Route: multiple
Dose: 500 mg, 4 times / day
Sources:
unhealthy, 70 years
n = 1
Health Status: unhealthy
Condition: Diabetes | Chronic Renal Failure
Age Group: 70 years
Sex: F
Population Size: 1
Sources:
Metabolic acidosis grade 3
500 mg 4 times / day multiple, oral
Studied dose
Dose: 500 mg, 4 times / day
Route: oral
Route: multiple
Dose: 500 mg, 4 times / day
Sources:
unhealthy, 70 years
n = 1
Health Status: unhealthy
Condition: Diabetes | Chronic Renal Failure
Age Group: 70 years
Sex: F
Population Size: 1
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >5000 uM]
weak [IC50 425 uM]
weak [IC50 816 uM]
yes [IC50 75 uM]
yes
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
weak
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Renal failure associated with acetazolamide therapy for glaucoma.
1975 Apr
Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review.
2000 Jul 29
Cerebellar Ataxia.
2000 May
Persistent nephrocalcinosis for acetazolamide and furosemide in a pediatric patient.
2000 Nov
Management strategies for refractory localization-related seizures.
2001
Diuretic therapy for newborn infants with posthemorrhagic ventricular dilatation.
2001
Vasoconstrictive drugs increase carbonic anhydrase I in vascular smooth muscle while vasodilating drugs reduce the activity of this isozyme by a direct mechanism of action.
2001
Carbonic anhydrase inhibitors for hypercapnic ventilatory failure in chronic obstructive pulmonary disease.
2001
Treatment options for sleep apnoea.
2001
Benign intracranial hypertension: correlation of cerebral blood flow with disease severity.
2001 Apr
Calcification in the planula and polyp of the hydroid Hydractinia symbiolongicarpus (Cnidaria, Hydrozoa).
2001 Aug
Acetazolamide poisoning in a toddler.
2001 Aug
Acetazolamide treatment for infantile central sleep apnea.
2001 Aug
Minocycline and Pseudotumor cerebri: The well-known but well-kept secret.
2001 Aug
Cerebrovascular reserve in patients with carotid occlusive disease assessed by stable xenon-enhanced ct cerebral blood flow and transcranial Doppler.
2001 Aug
Depolarization of the liver cell membrane by metformin.
2001 Aug 6
Beta-adrenergic blocker therapy and the trabecular meshwork.
2001 Feb
Effect of familial hypertension on glomerular hemodynamics and tubulo-glomerular feedback after uninephrectomy.
2001 Feb
Low-dose acetazolamide does affect respiratory muscle function in spontaneously breathing anesthetized rabbits.
2001 Feb
Asymmetric subcellular mRNA distribution correlates with carbonic anhydrase activity in Acetabularia acetabulum.
2001 Feb
Measurement of cerebral hemodynamics with perfusion-weighted MR imaging: comparison with pre- and post-acetazolamide 133Xe-SPECT in occlusive carotid disease.
2001 Feb
Long-term follow-up of asymptomatic patients with major artery occlusion: rate of symptomatic change and evaluation of cerebral hemodynamics.
2001 Feb
The spray drying of acetazolamide as method to modify crystal properties and to improve compression behaviour.
2001 Feb 1
Influence of nitrovasodilators and cyclooxygenase inhibitors on cerebral vasoreactivity in conscious rabbits.
2001 Feb 2
Assessment of cerebrovascular reactivity with functional magnetic resonance imaging: comparison of CO(2) and breath holding.
2001 Jan
[Benign intracranial hypertension].
2001 Jan
Quantitative volumetry in patients with carotid disease--effects of acetazolamide.
2001 Jan
In vivo evidence for K(Ca) channel opening properties of acetazolamide in the human vasculature.
2001 Jan
Uveal effusion after cataract surgery: an echographic study.
2001 Jan
Role of basolateral carbonic anhydrase in proximal tubular fluid and bicarbonate absorption.
2001 Jan
Use of acetazolamide to decrease cerebrospinal fluid production in chronically ventilated patients with ventriculopleural shunts.
2001 Jan
Cardiovascular effects of hypercarbia in rainbow trout (Oncorhynchus mykiss): a role for externally oriented chemoreceptors.
2001 Jan
Pharmacological prevention of acute mountain sickness. Same ascent rates must be used to assess effectiveness of different doses of acetazolamide.
2001 Jan 6
Pharmacological prevention of acute mountain sickness. Many climbers and trekkers find acetazolamide 500 mg/day to be useful.
2001 Jan 6
Idiopathic "benign" intracranial hypertension: case series and review.
2001 Jul
Clinical trial of acetazolamide in SCA6, with assessment using the Ataxia Rating Scale and body stabilometry.
2001 Jul
Reliable measurement of mouse intraocular pressure by a servo-null micropipette system.
2001 Jul
Anticonvulsant activity of omeprazole in rats.
2001 Jul
High-altitude illness.
2001 Jul 12
Extracellular carbonic anhydrase in the dogfish, Squalus acanthias: a role in CO2 excretion.
2001 Jul-Aug
[Mountaineering and altitude sickness].
2001 Jun
Serous macular detachments in a patient with IgM paraproteinemia: an optical coherence tomography study.
2001 Jun
Correlation of optic nerve head tomography with visual field sensitivity in papilledema.
2001 Jun
Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A.
2001 Jun
Sporadic late onset paroxysmal cerebellar ataxia in four unrelated patients: a new disease?
2001 Mar
Characterization of carbonic anhydrase from Neisseria gonorrhoeae.
2001 Mar
Heterosynaptic transformation of GABAergic gating in the hippocampus and effects of carbonic anhydrase inhibition.
2001 Mar
Remodeling the cellular profile of collecting ducts by chronic carbonic anhydrase inhibition.
2001 Mar
Acute mountain sickness score and hypoxemia.
2001 May
Transient renal tubular acidosis in a neonate following transplacental acetazolamide.
2001 May
Patents

Patents

Sample Use Guides

Glaucoma: The recommended dosage is 1 capsule (500 mg) two times a day. Usually 1 capsule is administered in the morning and 1 capsule in the evening. It may be necessary to adjust the dose, but it has usually been found that dosage in excess of 2 capsules (1 g) does not produce an increased effect Acute Mountain Sickness: Dosage is 500 mg to 1000 mg daily, in divided doses using tablets or extended-release capsules as appropriate. In circumstances of rapid ascent, such as in rescue or military operations, the higher dose level of 1000 mg is recommended
Route of Administration: Oral
In both, piriform and entorhinal cortices (PC and EC, respectively), acetazolamide (10 uM): (i) reduced the duration and the interval of ccurrence of ictal discharges along with the associated ripples and fast ripples; (ii) decreased the interval of occurrence of interictal discharges and the rates of associated fast ripples; and (iii)diminished the duration and amplitude of pharmacologically isolated GABAergic events while increasing their interval of occurrence.
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:35:37 UTC 2023
Edited
by admin
on Wed Jul 05 22:35:37 UTC 2023
Record UNII
O3FX965V0I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACETAZOLAMIDE
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
DEFILTRAN
Brand Name English
Acetazolamide [WHO-DD]
Common Name English
ATENEZO
Brand Name English
ACETAZOLAMIDE [USP-RS]
Common Name English
acetazolamide [INN]
Common Name English
ACETAZOLAMIDE [MART.]
Common Name English
NEPHRAMIDE
Common Name English
ACETAZOLAMIDE [EP MONOGRAPH]
Common Name English
ACETAZOLAMIDE [HSDB]
Common Name English
PHONURIT
Common Name English
ACETAZOLAMIDE [WHO-IP]
Common Name English
ACETAZOLAMIDE [MI]
Common Name English
ACETAMOX
Brand Name English
ACETAZOLAMIDE [JAN]
Common Name English
DIDOC
Brand Name English
DIAMOX
Common Name English
DIURIWAS
Brand Name English
NSC-145177
Code English
N-(5-(AMINOSULFONYL)-1,3,4-THIADIAZOL-2-YL)ACETAMIDE
Systematic Name English
ACETAZOLAMIDE [VANDF]
Common Name English
ACETAZOLAMIDE [ORANGE BOOK]
Common Name English
GLAUPAX
Brand Name English
EDEMOX
Brand Name English
ACETAMIDE, N-(5-(AMINOSULFONYL)-1,3,4-THIADIAZOL-2-YL)-
Systematic Name English
DONMOX
Brand Name English
ACETAZOLAMIDE [USP MONOGRAPH]
Common Name English
L 579486
Code English
N-(5-Sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide
Systematic Name English
ACETAZOLAMIDUM [WHO-IP LATIN]
Common Name English
ACETAZOLAMIDE [EP IMPURITY]
Common Name English
Classification Tree Code System Code
WHO-VATC QS01EC01
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
NCI_THESAURUS C448
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
NDF-RT N0000175517
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
CFR 21 CFR 522.44
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
NCI_THESAURUS C29577
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
WHO-ATC S01EC01
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
NDF-RT N0000000235
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 21.4
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
CFR 21 CFR 520.28
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
LIVERTOX NBK548664
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
Code System Code Type Description
NSC
145177
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
CHEBI
50634
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
LACTMED
Acetazolamide
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
INN
481
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
MERCK INDEX
M1322
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY Merck Index
ChEMBL
CHEMBL20
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
FDA UNII
O3FX965V0I
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
CHEBI
31163
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
EVMPD
SUB05219MIG
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
MESH
D000086
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
WIKIPEDIA
ACETAZOLAMIDE
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
CAS
59-66-5
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
CHEBI
27690
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
DAILYMED
O3FX965V0I
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
HSDB
3002
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
PUBCHEM
1986
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
SMS_ID
100000092652
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACPOEIA
ACETAZOLAMIDE
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY Description: A white, or almost white, crystalline powder; odourless. Solubility: Very slightly soluble in water; slightly soluble in ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Carbonic anhydrase inhibitor. Storage: Acetazolamide should be kept in a well-closed container. Definition: Acetazolamide contains not less than 99.0% and not more than 101.0% of C4H6N4O3S2, calculated with reference to the dried substance.
EPA CompTox
DTXSID7022544
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-440-5
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
NCI_THESAURUS
C28809
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
DRUG BANK
DB00819
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
DRUG CENTRAL
56
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
RS_ITEM_NUM
1005004
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
IUPHAR
6792
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY
RXCUI
167
Created by admin on Wed Jul 05 22:35:37 UTC 2023 , Edited by admin on Wed Jul 05 22:35:37 UTC 2023
PRIMARY RxNorm
Related Record Type Details
TARGET -> INHIBITOR
Ki
TARGET -> INHIBITOR
Ki
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
TARGET -> INHIBITOR
Ki
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
Ki
TRANSPORTER -> INHIBITOR
TARGET -> INHIBITOR
Ki
TRANSPORTER -> INHIBITOR
TARGET -> INHIBITOR
Ki
BINDER->LIGAND
BINDING
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
Ki
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC